G1 Therapeutics

	A	B	C	D	E	F	G	H	I	J
1	NAMES/DATE	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022
2	Assets	256,514	253,597	258,232	228,552	308,558	276,755	243,497	254,094	218,239
3	Cash and cash equivalents	242,465	234,33	238,405	207,306	278,968	244,023	212,089	221,186	183,02
4	Liabilities	27,064	49,752	60,76	51,201	63,115	63,559	65,158	110,553	118,107
5	Total Revenue	-	2,14	26,599	16,546	14,218	6,604	4,858	5,8	6,902
6	Product Revenue	-	-	-	-	0,609	2,532	3,576	4,4	5,48
7	License Revenue	-	2,14	26,599	16,546	13,609	4,072	1,282	1,4	1,422
8	Operating expenses:	31,821	32,962	36,344	40,634	39,753	44,796	46,002	43,382	53,683
9	Cost of goods sold	-	-	-	-	0,243	0,808	0,591	0,374	0,669
10	Research and development	20,434	18,531	17,932	16,374	16,54	18,752	21,143	19,79	26,305
11	Selling, general and administrative	11,387	14,431	18,412	24,26	22,97	25,236	24,268	23,218	26,709
12	Net loss	31,023	31,21	11,674	25,347	26,442	39,422	42,468	40,02	49,192
13
14	На основе данных macrotrends и отчетов G1 Therapeutics.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100